A Phase II Study With a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15

The main part of this trial is a phase II study of vosaroxin with azacitidine in older patients with newly diagnosed AML and intermediate or adverse genetic risk or MDS-EB-2. An initial safety run-in phase of the study will be performed administering the study drug vosaroxin with azacitidine in up to 18 patients. After completion of the run-in phase, toxicity and response data will be provided to the external Data and Safety Monitoring Board (DSMB) and the Trial Committee by the Coordinating Investigator. The Trial Committee will decide on the basis of these data and the recommendation of the DSMB on dose modification and the vosaroxin dose for the phase II part of the study, which will include 150 patients in total.

开始日期2018-04-19

申办/合作机构

Universität Ulm

[+1]

NCT02658487

/ Completed临床2期IIT

Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML

This phase II trial studies how well vosaroxin and cytarabine work in treating patients with untreated acute myeloid leukemia. Drugs used in chemotherapy, such as vosaroxin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

开始日期2016-03-01

申办/合作机构

The Vanderbilt-Ingram Cancer Center

[+1]

NCT02485353

/ TerminatedN/AIIT

Pilot Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML

This is a pilot efficacy assessment clinical trial of vosaroxin and cytarabine for the treatment of adults 60 years of age or older with previously untreated acute myeloid leukemia. A total of 17 evaluable patients are planned to be treated on the study.

开始日期2015-10-20

申办/合作机构

The Indiana University School of Medicine

100 项与伏利拉辛相关的临床结果

登录后查看更多信息

100 项与伏利拉辛相关的转化医学

登录后查看更多信息

100 项与伏利拉辛相关的专利（医药）

登录后查看更多信息

项与伏利拉辛相关的文献（医药）

2025-03-01·Chemical Biology & Drug Design

Synthesis of New Thiazole‐Pyrazole Analogues: Molecular Modelling, Antiproliferative/Antiviral Activities, and ADME Studies

Article

作者: El‐Metwaly, Nashwa M. ; Alsharif, Shaker T. ; Attar, Roba M. S. ; Imam, Mohammed A. ; Almughathawi, Renad ; Alshammari, Nadiyah M. ; Siddiq, Hind A. ; Halawani, Nuha M.

ABSTRACT:

Twelve thiazole‐pyrazole analogues 4, 6, and 8 were synthesized by introducing various pyrazole systems into the core, 2‐((4‐acetylphenyl)amino)‐4‐methylthiazole (2), through many synthetic approaches. The density functional theory (DFT) study of the synthesized analogues revealed coincided configurations of their highest occupied and lowest unoccupied molecular orbitals (HOMO and LUMO), except for the nitro derivatives, in which the intramolecular charge‐transfer (CT) may be denoted as π → π* and n → π*. In addition, the in vitro antiproliferative efficacy towards some cancer cell lines was examined (Panc‐1, HT‐29, MCF‐7) and the non‐cancerous (WI‐38), using Dasatinib (Reference). The analogues 4c and 4d demonstrated the most potent anticancer effect, particularly against Panc‐1 and MCF‐7 cells. Moreover, the antiviral activity against H5N1, using a plaque reduction assay, showed that analogue 6a exhibited the most potent antiviral activity (100% inhibition and TC50 = 61 μg/μL), comparable to the reference drug amantadine (TC50 = 72 μg/μL, 100% inhibition). Furthermore, the molecular docking disclosed that the analogues exhibited a range of interactions, such as H‐bonding and π‐π stacking, with binding affinities between −4.8558 and − 8.3673 kcal/mol. Additionally, the SwissADME predictions indicated that the synthesized analogues possess promising drug‐like characteristics, but analogues 4a–d and 8c demonstrated inadequate solubility and bioavailability, which restricts their use as viable oral medications.

2024-05-01·JOURNAL OF MOLECULAR STRUCTURE

Thiazole moiety: A promising scaffold for anticancer drug discovery

作者: Raed H. Althomali ; Walaa I. El-Sofany ; Manal M. Anwar ; Asmaa F. Kassem

A review.Over the past few decades, significant advancements in the discovery of anticancer medicines have yielded various novel agents, both synthetic and natural in origin.Thiazoles are a special type of heterocyclic compound with five members that comprise nitrogen and sulfur atoms.These compounds are vital core scaffolds in a number of significant pharmaceutical drugs including anticancer.It was discovered that several chemotherapy drugs have some naturally occurring chems. and a thiazole nucleus.Some clin. used anticancer medications have thiazole nucleus as a basic component including Vosaroxin, Dabrafenib, patellamide A, dasatinib, epothilones, ixabepilone, tiazofurin, Kud 773, and bleomycin.Recently, thiazole-containing compounds have been effectively developed as possible inhibitors of several anti-cancer targets, including enzyme-linked receptor(s) found on the cell membrane (i.e., polymerase inhibitors) and the cell cycle (i.e., microtubular inhibitors).Addnl., it has been demonstrated that these substances exhibit low toxicity, strong anticancer activity, and great efficacy.The biol. importance of thiazoles in the creation of anticancer medications is discussed in this article, which also reviews recent research on the subject.The results may help in the development of more potent and precisely tailored anticancer medications.

2024-01-01·Biochemistry Research International

Evaluation of the Antibacterial and Antioxidant Properties of Chemical Constituents of the Roots of Woodfordia uniflora: An Integrated Approach of Experimental and Computational Study

Article

作者: Milkyas Endale ; Yadessa Melaku ; Daniel Rentsch ; Kebede Shenkute ; Bihon Abera ; Mo Hunsen ; Negera Abdissa ; Rajalakshmanan Eswaramoorthy ; Urgessa Ensermu

Woodfordia uniflora is a medicinal plant used for the treatment of malaria, toothache, and stomach problems. The root parts of the plant are also used for healing liver disorders. Silica gel chromatography separation of CH2Cl2/MeOH (1:1) and MeOH extracts of roots of W. uniflora result in the isolation of three compounds, namely, bergenin (1), β‐sitosterol (2), and epigallocatechin 3‐gallate (3), reported herein for the first time from the plant. The structure of the isolated compounds was elucidated using NMR (1D and 2D) techniques. Disk diffusion and DPPH assay were used to evaluate the antibacterial and antioxidant activities, respectively. Molecular docking was done by the AutoDock Vina 4.2 program. The pharmacokinetics and toxicity profile of compounds were predicted by Swiss ADME and Pro Tox II online servers. GC‐MS analysis roots of W. uniflora result in the identification of five compounds, of which palmitic acid (34.9%) was the major constituent. The antibacterial activity result indicated that the oil extract had promising activity against P. aeruginosa, E. coli, S. pyogenes, and S. aureus with IZ of 14.3 ± 0.81, 15.0 ± 0.0, 15.6 ± 0.47, and 17.6 ± 0.47 mm, respectively, at 5 mg/mL, compared to ciprofloxacin (1Z 27–30.0 ± 0.0 mm) at 30 μg/mL. MeOH and CH2Cl2/MeOH (1:1) extract showed inhibition against E. coli (IZ of 13.6 ± 0.47 mm) and P. aeruginosa (IZ of 10.0 ± 0.0 mm), respectively, at 200 mg/mL. Bergenin (1) and β‐sitosterol (2) also displayed maximum inhibition of E. coil (IZ of 11.6 ± 0.47) and S. aureus (11.0 ± 0.0 mm), respectively, at 5 mg/mL. The antioxidant activity results showed that CH2Cl2/MeOH (1:1) and MeOH extracts, bergenin (1), and compound 3 displayed potent scavenging DPPH radical with a percentage of inhibition of 76.8 ± 0.12, 77.8 ± 0.08, 71.4 ± 0.08, and 91.2 ± 0.16, respectively, compared to ascorbic acid (93.2% ± 0.04%) at 100 μg/mL. The molecular docking analysis showed that all compounds (1–3) exhibited minimum binding energy toward PDB ID: 1HD2 (−5.2 to −6.3 kcal/mol), compared to ascorbic acid (−5.6 kcal/mol), and toward PDB ID: 1DNU (−8.0 to −10.7 kcal/mol) receptors, compared to ascorbic acid (−5.7 kcal/mol). Toward the PDB ID: 4FM9 receptor, β‐sitosterol (2) and compound 3 exhibited the best binding free energy of −9.1 and −9.8 kcal·mol, respectively, compared to vosaroxin (−7.8 kcal/mol). The drug‐likeness analysis result indicated that bergenin (1) and β‐sitosterol (2) obeyed four and five criteria of Lipinski’s rule, respectively, and are more likely to be administered orally. The in silico toxicity analysis showed none of the compounds would be cytotoxic, mutagenic, or hepatotoxic. The in vitro antioxidant and antibacterial results supported by in silico analysis demonstrated that the roots of W. uniflora have the potential to be therapeutic agents for bacterial infections and free radical–inducing diseases.

项与伏利拉辛相关的新闻（医药）

2026-03-31

·今日头条

创新药 ADC赛道 10家核心公司全景解析

1. 荣昌生物作为国产ADC赛道的先行者与商业化龙头，荣昌生物聚焦肿瘤与自身免疫领域，构建了覆盖ADC、抗体融合蛋白等多模态的创新管线。核心产品维迪西妥单抗是中国首个原创ADC药物，也是国内唯一同时获中美FDA与NMPA突破性疗法认定的ADC，靶向HER2靶点，采用独特的可裂解连接子与MMAE毒素组合，通过“旁观者效应”提升杀伤效果，已获批胃癌、尿路上皮癌、乳腺癌等多项适应症，医保谈判落地后放量加速。其核心竞争力在于自主可控的ADC技术平台与全球化布局，2021年与西雅图基因达成超26亿美元的海外授权交易，刷新中国单品种出海纪录，同时与艾伯维等跨国药企深化合作，持续推进新一代ADC与联合疗法研发，是国产ADC实现全球竞争力的核心标杆。 2. 科伦博泰依托母公司科伦药业的全产业链支撑，科伦博泰是国内ADC领域技术平台领先、全球化合作深度最深的企业，核心布局肿瘤治疗领域，拥有自主研发的OptiDC ADC技术平台，覆盖靶点设计、连接子优化、毒素筛选全流程。核心产品芦康沙妥珠单抗（SKB264）为全球第二款、国内首款TROP2 ADC，已获批三阴性乳腺癌、EGFR突变非小细胞肺癌等适应症，在晚期实体瘤中展现出优于传统疗法的疗效，2025年多项三期临床数据在《新英格兰医学杂志》等顶刊发表。其核心壁垒在于与默沙东的深度绑定，累计合作金额超100亿美元，负责其全球临床开发与商业化，同时CLDN18.2、HER3等多款ADC管线全球进度领先，依托母公司的生产与渠道优势，实现研发、生产、商业化一体化闭环，成为国产ADC全球化的核心载体。 3. 恒瑞医药作为国内创新药绝对龙头，恒瑞医药以ADC为核心增长点，构建了靶点多元化、适应症全覆盖的肿瘤ADC管线，覆盖HER2、TROP2、HER3、Claudin18.2等热门靶点。核心产品瑞康曲妥珠单抗（SHR-A1811）是国内首个获批用于HER2突变非小细胞肺癌的ADC，采用手性环丙基修饰的可裂解连接子，优化DAR值至6:1，兼顾疗效与安全性，在HER2阳性乳腺癌中实现中位无进展生存期30.6个月的突破性数据。其核心优势在于全产业链整合能力，从药物研发、生产制造到临床推广形成闭环，拥有8项突破性疗法认定，与默克达成超10亿美元的海外授权，同时推进多靶点联合疗法研发，凭借庞大的临床资源与商业化团队，快速兑现ADC产品业绩，是国产ADC商业化规模的核心引领者。 4. 百利天恒百利天恒以双抗ADC技术实现全球首创，成为ADC赛道的差异化黑马，聚焦实体瘤治疗，核心管线BL-B01D1是全球首个进入三期临床的EGFR×HER3双特异性ADC，同时靶向两个肿瘤相关靶点，解决传统单靶点ADC的耐药与靶点表达局限问题。临床数据显示，该药在非小细胞肺癌、食管癌、乳腺癌等多癌种中疗效显著，食管癌二线治疗三期临床达到PFS与OS双终点，填补该领域ADC空白。核心竞争力在于First-in-class技术壁垒与全球化合作，与百时美施贵宝达成总额超84亿美元的全球合作，覆盖开发与商业化，国内推进11项三期临床，覆盖6大实体瘤，同时布局双抗、多特异性抗体等多模态管线，成为下一代ADC技术的核心探索者。 5. 信达生物信达生物以差异化CLDN18.2 ADC为核心，深耕肿瘤治疗领域，构建了覆盖ADC、双抗、小分子的创新管线矩阵。核心产品IBI343是靶向Claudin18.2的新一代ADC，采用定点偶联技术与Exatecan毒素，DAR值稳定为4，兼具抗体样药代动力学与 widened治疗指数，在晚期胃/胃食管交界处腺癌中展现出高效低毒的临床特征，I期数据发表于《Nature Medicine》顶刊，国际多中心三期临床同步推进。其核心优势在于全球化研发能力与学术影响力，与武田制药深化全球合作，同步推进国内与国际临床开发，依托成熟的商业化团队，快速实现医保准入与市场渗透，同时布局EGFR/B7H3、DLL3等前沿靶点ADC，持续丰富管线厚度，成为国产ADC国际化的重要力量。 6. 再鼎医药再鼎医药以DLL3 ADC突破小细胞肺癌治疗困境，聚焦难治性肿瘤领域，核心产品Zocilurtatug Pelitecan（ZL-1310）是全球首款靶向DLL3的ADC，针对小细胞肺癌这一“冷肿瘤”，DLL3靶点在近90%小细胞肺癌细胞表面高表达，正常组织几乎不表达，特异性极强。临床数据惊艳，二线小细胞肺癌客观缓解率达67%-79%，脑转移患者客观缓解率达80%-100%，≥3级不良事件发生率仅6%，安全性优异，已获FDA孤儿药资格，全球三期临床正式启动。其核心竞争力在于精准切入未满足临床需求赛道，与全球顶尖临床机构合作推进研究，同时布局神经内分泌癌等相关适应症，依托灵活的全球化BD策略，快速实现产品全球权益布局，成为小细胞肺癌ADC领域的全球领跑者。 7. 映恩生物映恩生物以下一代ADC技术平台为核心，聚焦肿瘤与罕见病领域，是国内ADC技术迭代的核心代表。公司构建了涵盖双抗ADC、免疫刺激型ADC、双毒素ADC等多技术路线的管线，核心产品DB106为靶向TROP2的双抗ADC，相比单靶点ADC，进一步提升肿瘤靶向性与杀伤效果，在晚期实体瘤中展现出优异的临床数据。其核心壁垒在于自主创新的技术平台与差异化管线布局，多项技术获全球专利授权，与BioNTech等国际药企合作开发联合疗法，同时布局Claudin18.2、B7H3等新兴靶点ADC，聚焦First-in-class与Best-in-class产品，凭借灵活的合作模式与技术输出能力，快速跻身全球ADC第一梯队，成为国产ADC技术创新的重要标杆。 8. 乐普生物乐普生物依托心血管领域的资源优势，跨界布局ADC赛道，聚焦肿瘤与自身免疫疾病，核心管线MRG003为靶向EGFR的ADC，在晚期实体瘤中展现出良好的疗效与安全性，尤其在头颈部鳞癌中表现突出，多项临床数据入选国际学术会议。其核心优势在于全产业链整合与临床转化能力，依托母公司的生产制造平台，实现ADC药物的自主生产与质量控制，同时与国内顶尖肿瘤医院合作，快速推进临床研究，布局PD-L1、Claudin18.2等多靶点ADC，形成差异化竞争格局，凭借心血管领域的渠道资源，快速实现ADC产品的市场渗透，成为国产ADC领域的重要参与者。 9. 石药集团石药集团以成熟的ADC技术与丰富的管线布局，成为ADC赛道的稳健型玩家，聚焦肿瘤治疗领域，核心产品SYS6002为靶向Claudin18.2的ADC，已进入二期临床，在晚期胃癌中展现出初步疗效，同时布局HER2、TROP2等热门靶点ADC，形成多靶点协同布局。其核心竞争力在于制药全产业链经验与资金实力，依托数十年的制药积累，构建了完善的研发、生产与商业化体系，能够快速推进ADC管线的临床转化与市场落地，同时与国际药企深化合作，引入先进技术与临床资源，持续优化ADC产品的疗效与安全性，凭借庞大的销售网络，快速实现ADC产品的市场覆盖，成为国产ADC商业化的重要补充力量。 10. 宜联生物宜联生物以高端ADC技术与差异化靶点布局，聚焦肿瘤治疗领域，核心管线YL202为靶向Claudin18.2的ADC，与BioNTech联合开发，采用独特的连接子与毒素设计，在晚期胃/胃食管交界处癌中展现出优异的临床数据，多项研究入选ELCC 2026等国际学术会议。其核心优势在于国际合作与技术协同，依托与BioNTech的深度合作，共享全球前沿技术与临床资源，快速推进管线全球开发，同时布局EGFR、B7H3等新兴靶点ADC，聚焦未满足临床需求的癌种，凭借灵活的BD策略与技术创新能力，快速跻身国内ADC第一梯队，成为国产ADC国际化的新兴力量。免责声明：根据公开市场资料整理，不构成投资建议，仅供参考交流。

2024-04-25

·GlobeNewswire-Health Care

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation EMERYVILLE, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $9 million milestone related to the U.S. Food and Drug Administration’s (FDA) approval of Day One Biopharmaceuticals’ New Drug Application (NDA) for OJEMDA™ (tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. “This is an important milestone for XOMA and our royalty portfolio, but more importantly, it is a watershed event for children living with low-grade gliomas with BRAF alterations that have relapsed or progressed,” stated Owen Hughes, Chief Executive Officer of XOMA. In March 2021, XOMA paid $13.5 million upfront to acquire the $54 million in potential milestones and mid-single digit royalties associated with tovorafenib, plus a share of potential event-based economics, in addition to the economics associated with vosaroxin, from Viracta Therapeutics. About XOMA CorporationXOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. Forward-Looking Statements/Explanatory Notes Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA and other developments related to OJEMDA™ (tovorafenib) and the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. In some cases, you can identify such forward-looking statements by terminology such as “expect,” “may,” “will”, or “could,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except OJEMDA™ (tovorafenib), VABYSMO® (faricimab-svoa), IXINITY® [coagulation factor IX (recombinant)], DSUVIA® (sufentanil sublingual tablet), are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. XOMA Investor ContactXOMA Media ContactJuliane SnowdenKathy VincentXOMA CorporationKV Consulting & Management+1-646-438-9754+1-310-403-8951juliane.snowden@xoma.comkathy@kathyvincent.com

上市批准加速审批

2023-10-31

·GlobeNewswire-Health Care

XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance of Day One Biopharmaceuticals’ New Drug Application (NDA) for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has granted tovorafenib Priority Review and established a Prescription Drug User Fee Act (PDUFA) date of April 30, 2024. “Tovorafenib has the potential to address a key unmet need in children whose low-grade gliomas with BRAF alterations have relapsed or progressed,” stated Owen Hughes, Executive Chairman of XOMA. “A novel, targeted, orally available option has the opportunity to set a new standard-of-care in this patient population.” In March 2021, XOMA paid $13.5 million upfront plus a share of a future event-based milestone, to acquire the $54 million in potential milestones and mid-single digit royalties associated with tovorafenib, in addition to the economics associated with vosaroxin, from Viracta Therapeutics. About XOMA CorporationXOMA is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com. Forward-Looking Statements/Explanatory NotesCertain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential commercial payments to XOMA and other developments related to tovorafenib and the potential of XOMA’s portfolio of partnered programs and licensed technologies generating substantial milestone and royalty proceeds over time. In some cases, you can identify such forward-looking statements by terminology such as “expect,” “may,” “will”, or “could,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that our product candidates subject to out-license agreements are still being developed, and our licensees may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for the products in which we have an ownership or royalty interest; if the therapeutic product candidates to which we have a royalty interest do not receive regulatory approval, our third-party licensees will not be able to market them; and the impact to the global economy as a result of the COVID-19 pandemic. Other potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statement in this press release represents XOMA's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, all assets in XOMA’s milestone and royalty portfolio, except VABYSMO® and IXINITY®, are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. XOMA Investor ContactXOMA Media ContactJuliane SnowdenKathy VincentXOMA CorporationKV Consulting & Management+1 646-438-9754+1 310-403-8951juliane.snowden@xoma.comkathy@kathyvincent.com

优先审批申请上市

100 项与伏利拉辛相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08024	伏利拉辛	L01XX53	DB11999

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性髓性白血病	申请上市	欧盟	Sunesis Pharmaceuticals, Inc.	-
前体B细胞成淋巴细胞白血病淋巴瘤	临床3期	丹麦	-	2011-03-13
难治性急性髓细胞白血病	临床3期	美国	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床3期	澳大利亚	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床3期	奥地利	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床3期	比利时	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床3期	加拿大	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床3期	捷克	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床3期	法国	Sunesis Pharmaceuticals, Inc.	2010-12-17
难治性急性髓细胞白血病	临床3期	德国	Sunesis Pharmaceuticals, Inc.	2010-12-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01893320 (CTgov)	临床1/2期	急性髓性白血病 \| 骨髓增生异常综合征	66	Decitabine+Vosaroxin	膚願鏇繭觸鹽觸憲糧繭 = 簾簾鏇選齋淵廠糧積淵醖繭鏇廠鹽艱積壓網廠 (廠築遞醖醖鏇餘鑰膚網, 願鏇鬱鏇蓋襯廠餘範鑰 ~ 艱積襯糧壓選鏇夢窪餘)	-	2022-02-09
NCT01980056 (CTgov)	临床1/2期	高危骨髓增生异常综合征	10	Vosaroxin (All Study Participants)	淵衊繭遞鏇築築鹽齋顧 = 積積襯膚醖鏇衊淵糧範製範獵餘獵蓋鏇醖築廠 (醖簾鏇廠築憲廠淵膚醖, 衊蓋衊餘廠艱艱獵淵艱 ~ 窪範選製醖鏇淵膚鑰願)	-	2018-12-28
				Vosaroxin (Vosaroxin: Dose Level 1: Vosaroxin 50 mg/m^2 IV on Days 1 & 4)	壓餘廠衊餘夢膚鬱壓壓 = 廠膚窪齋築齋鬱蓋齋築觸築艱積膚選夢廠範鏇 (壓窪淵簾憲醖廠糧艱顧, 積鹹製壓醖廠鑰壓積壓 ~ 鬱築膚積鹹獵選積網簾)
NCT00298896 (CTgov)	临床2期	小细胞癌 \| 小细胞肺癌	55	SNS-595	繭構糧顧艱鹽衊鬱鹹鬱 = 淵構顧獵糧築範鏇膚廠衊蓋積鑰夢簾願遞蓋簾 (積鬱鏇襯選醖窪構鏇顧, 齋製蓋鑰膚鹹憲簾糧顧 ~ 窪蓋構窪築憲壓鏇襯築) 更多	-	2018-07-26
NCT01893320 (Pubmed)	临床2期	急性髓性白血病 \| 高危骨髓增生异常综合征	65	Vosaroxin 90 mg/m2	範鹹廠製糧顧網觸簾膚(製簾餘壓網遞壓觸膚糧) = 餘製獵積餘夢範醖範選齋憲鑰鬱觸夢壓廠獵顧 (蓋壓壓願襯窪遞顧製範 ) 更多	-	2017-10-01
				Vosaroxin 70 mg/m2	範鹹廠製糧顧網觸簾膚(製簾餘壓網遞壓觸膚糧) = 糧醖積夢廠觸憲鹹遞糧齋憲鑰鬱觸夢壓廠獵顧 (蓋壓壓願襯窪遞顧製範 ) 更多
NCT02485353 (CTgov)	N/A	急性髓性白血病	2	Vosaroxin+Cytarabine	範艱範壓襯觸鹽膚顧醖 = 顧蓋廠網鹹壓積鹽鑰艱製艱獵構獵鏇鏇淵網糧 (淵鏇網觸觸鏇艱糧壓積, 鏇廠製鑰簾製願鬱願鏇 ~ 鬱衊範鑰鏇憲遞鬱衊繭) 更多	-	2017-09-20
EHA2017	临床1期	骨髓增生异常综合征	35	Vosaroxin plus Azacitidine	繭簾鏇繭齋獵壓積製獵(夢積壓鹽繭淵齋糧壓遞) = Incidences of ≥ grade 3 non-hematologic adverse events considered possibly, probably, or definitely drug-related for the total cohort (n=35) included infections (n=38), non-neutropenic fever (n=1); neutropenic fever (n=23); bleeding (n=9); and GI (mucositis/colitis/dysphagia; n=4). Two deaths were considered possibly treatment-related (sepsis and diffuse alveolar hemorrhage). No cardiac toxicity attributable to study treatment was observed, even with prolonged therapy. 廠構憲構膚膚衊壓衊製 (觸遞窪遞衊憲繭鏇積鬱 )	积极	2017-05-18
NCT01191801 (VALOR, CTgov)	临床3期	难治性急性髓细胞白血病	711	Vosaroxin+Cytarabine (Group A (Vosaroxin/Cytarabine))	繭構膚範餘醖鑰淵繭窪(夢築範壓願鹽蓋鹽構衊) = 壓範鬱膚鹽簾膚窪顧簾願繭廠遞願鹹襯選鏇膚 (簾糧齋壓顧鑰鹽遞鏇鑰, 範衊顧鹽壓獵衊齋範廠 ~ 艱蓋廠壓淵簾醖蓋築鑰) 更多	-	2017-05-09
				Placebo+Cytarabine (Group B (Placebo/Cytarabine))	繭構膚範餘醖鑰淵繭窪(夢築範壓願鹽蓋鹽構衊) = 範窪夢網襯憲壓醖網壓願繭廠遞願鹹襯選鏇膚 (簾糧齋壓顧鑰鹽遞鏇鑰, 壓膚選選憲夢遞範網壓 ~ 襯簾簾觸壓餘糧築膚範) 更多
NCT01191801 (VALOR, Pubmed \| Lancet Oncol) 人工标引	临床3期	急性髓性白血病	711	cytarabine+Vosaroxin	選壓衊製網網繭製鏇憲(壓艱鬱獵築鬱獵艱遞艱) = 願鹽鹽鹹糧築憲繭鏇繭選觸願遞蓋鏇顧構鬱顧 (夢觸齋遞選鏇獵積網觸, 6.4 ~ 8.5) 更多	积极	2015-09-01
				cytarabine+Placebo	選壓衊製網網繭製鏇憲(壓艱鬱獵築鬱獵艱遞艱) = 築顧壓繭顧廠遞壓網鬱選觸願遞蓋鏇顧構鬱顧 (夢觸齋遞選鏇獵積網觸, 5.2 ~ 7.1) 更多
NCT01191801 (VALOR, EHA2015)	临床3期	难治性急性髓细胞白血病	451	Vosaroxin plus cytarabine	選淵襯積壓構遞壓餘構(遞齋構鬱夢積積網顧鹽) = 壓願膚範鑰廠選製淵膚鏇鑰鬱繭餘廠衊憲壓廠 (顧遞窪顧築壓齋蓋願衊 ) 更多	积极	2015-05-21
				Placebo plus cytarabine	選淵襯積壓構遞壓餘構(遞齋構鬱夢積積網顧鹽) = 憲齋糧襯選鏇鏇鏇衊鏇鏇鑰鬱繭餘廠衊憲壓廠 (顧遞窪顧築壓齋蓋願衊 ) 更多